Kane Biotech expands commercial activities in the United States.

Kane Biotech is expanding commercial activities in the United States while promoting its revyve wound-care products; those products are U.S. FDA 510(k) cleared and two are also Health Canada approved.

Kane Biotech Inc. is expanding its commercial activities in the United States. The company develops wound care treatments designed to disrupt biofilms and influence healing outcomes. The article highlights that biofilms are a major contributor to antibiotic resistance in wounds and can lead to serious clinical outcomes and cost. Kane Biotech presents its revyve product line as addressing both biofilms and wound bacteria. Key facts: - Kane Biotech is commercializing wound care treatments that disrupt biofilms. - revyve Antimicrobial Wound Gel, revyve Antimicrobial Wound Gel Spray and revyve Antimicrobial Skin and Wound Cleanser are U.S. FDA 510(k) cleared. - revyve Antimicrobial Wound Gel and revyve Antimicrobial Wound Gel Spray are also Health Canada approved. - The article reports that biofilms contribute to antibiotic resistance in wounds and can result in serious clinical outcomes and increased cost. - The article mentions the company trades under TSX-V:KNE. Summary: The company frames its U.S. commercial expansion alongside regulatory clearances for its revyve products, which it says address biofilms and wound bacteria. The article does not provide details on distribution scale, specific commercial plans, or timelines. Undetermined at this time.